When compared with demographically matched controls, patients with OBS have:

- significantly reduced work productivity
- less sexual satisfaction and more erectile dysfunction
- higher rates of depressive symptoms
- significantly poorer mental health
- poorer quality of sleep.

Postmenopausal women with urge incontinence have a significantly higher risk of falling and sustaining a fracture than women without urge incontinence.

Causes

The symptoms of OBS have many potential causes and contributing factors. Normal storage of urine is dependent on spinal reflex mechanisms that activate sympathetic and somatic pathways to the urethral outlet and tonic inhibitory systems in the brain that suppress the parasympathetic excitatory outflow to the urinary bladder.

Overactive bladder syndrome can have a significant effect on quality of life, and affects 12–17% of the population. Prevalence increases with age. The management of overactive bladder syndrome involves exclusion of underlying pathology. First line treatment includes lifestyle interventions, pelvic floor exercises, bladder training and antimuscarinic agents. Failure of conservative management necessitates urology referral. Second line therapies are more invasive, and include botulinum toxin, neuromodulation or surgical interventions such as augmentation cystoplasty or urinary diversion.

Keywords

overactive urinary bladder; urological diseases; urinary incontinence

Overactive bladder syndrome (OBS) is a symptom complex consisting of urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence (Table 1). It is not explained by metabolic (e.g., diabetes) or local pathological factors (e.g., infection, stones, urothelial cancer).1–6 Urgency is the key symptom of OBS.8

Clinical significance

In Australia, prevalence of urinary incontinence has been reported at 42% and the incidence of urge-only incontinence at 16%.7 Worldwide prevalence of OBS is 12.8% for women and 10.8% for men.8 The prevalence of all incontinence increases with age.7,8 Appropriate management can decrease both morbidity and costs.9
Diagnosis

Overactive bladder syndrome is a diagnosis of exclusion. A focused history, including past history of urogenital disorders, in combination with physical examination of the genitourinary system and relevant pelvic examinations should be performed as there are multiple conditions that can cause or contribute to symptoms of overactive bladder.\textsuperscript{4,17} Initial and secondary investigations are listed in Table \textsuperscript{2}.

Postvoid residual volume (PVR)\textsuperscript{2} is best measured with ultrasound (bladder scan or formal ultrasound), with the upper limit of normal being 30 mL.\textsuperscript{2} An initially raised PVR requires confirmation before being considered significant\textsuperscript{2} as it can be subject to error.

Increased PVR may contribute to urinary frequency and nocturia, and commencing anticholinergic medications in a patient with increased PVR may worsen bladder function and potentiate urinary retention.\textsuperscript{18}

A frequency/volume chart can exclude 24-hour polyuria due to diabetes insipidus, and nocturnal polyuria. It is an invaluable tool in OBS as it gives a better picture of the pattern of voiding than can be obtained from the symptoms alone.\textsuperscript{1} Three-day voiding diaries are as reliable as seven-day diaries.\textsuperscript{2} Information obtained should include number of voids in daytime, night time, 24 hour period, volume of urine over 24 hours, maximum voided volume, average voided volume, median maximum voided volume, and nocturnal urine volume. An assessment of severity of incontinence in terms of leakage episodes and pad usage\textsuperscript{2} can also be obtained.

Secondary investigations should be considered in patients with neurological disease, refractory OBS, or those in whom initial investigations raise the suspicion of an underlying problem that may require further evaluation or treatment\textsuperscript{19} (Table \textsuperscript{3}).

Urodynamic testing aims to demonstrate incontinence objectively and differentiate between different types of incontinence, so that the most effective method of treatment can be selected. Urodynamic investigations should also be used to demonstrate the presence of specific abnormalities before undertaking complex reconstructive urological procedures.\textsuperscript{20}

Urine cytology, performed on three voided specimens obtained on three separate days, has a variable sensitivity for the detection of urothelial carcinoma.\textsuperscript{21} Urine cytology is effective for screening for high grade lesions (sensitivity at least 90%, specificity 98–100%) and carcinoma in situ. However, it is unreliable for detection of well differentiated, low grade lesions.\textsuperscript{21}

Cystoscopy is indicated in patients with sterile haematuria and risk factors for bladder cancer, and in patients with recurrent urinary tract infections. Carcinoma in situ and other intravesical abnormalities can be assessed via cystoscopy. The possibility of prostate cancer should also be considered in men and assessed based on prostate-specific antigen, digital rectal examination findings and relevant risk factors.\textsuperscript{4}

---

**Table 1. Definitions of overactive bladder syndrome**

| Detrusor overactivity | A urodynamic observation characterised by involuntary spontaneous or provoked detrusor contractions during the filling phase\textsuperscript{4,12} |
| Nocturnal polyuria | An excess (>20–30%) proportion of urine excretion at night\textsuperscript{2} |
| Polyuria | >40 mL urine/kg body weight during 24 hours |
| Postvoid residual volume | The volume of fluid remaining in the bladder at the completion of micturition\textsuperscript{2} |
| Urgency | A sudden, compelling desire to void that is difficult to defer\textsuperscript{4,6} |
| Urinary frequency | >8 micturitions/24 hours |
| Urgency urinary incontinence | Involuntary loss of urine associated with urgency\textsuperscript{2} |

**Table 2. Investigations for overactive bladder syndrome**

**Initial investigations\textsuperscript{42}**

- Urinalysis to exclude infection, haematuria and glycosuria
- Urinary tract ultrasound and measurement of postresidual volume
- Frequency/volume chart for at least 3 days
- Bladder diary for a minimum of 3 days

**Secondary investigations\textsuperscript{19}**

- Urine cytology
- Urodynamic testing
- Cystoscopy
- Imaging of upper urinary tract or spine

---

**Table 3. Indications for urodynamic assessment\textsuperscript{17}**

**Suspicion of occult diagnosis that may alter management**

- Bladder outlet obstruction
- Detrusor hyperactivity with impaired contractility
- Impaired bladder compliance
- Dysfunctional voiding
- Mixed incontinence

**Risk of upper urinary tract deterioration**

- History of pelvic irradiation
- Radical pelvic surgery (abdomino-perineal resection, radical hysterectomy)
- Spina bifida
- Neurogenic voiding dysfunction (eg. multiple sclerosis, spinal cord injury)

**Other**

- Failed or unsatisfactory response to empiric medical therapy
- Uncertain diagnosis
- Unaware incontinence
- Prior lower urinary tract surgery (eg. transurethral resection of prostate, anti-incontinence surgery)
- Irreversible, potentially morbid intervention planned (ie. augmentation cystoplasty)
**Treatment**

Principles of treatment are to reduce urinary incontinence by changing patient behaviour and teaching continence skills.\(^{22}\)

Up to one-third of women with urge only incontinence can undergo spontaneous resolution at 2 years.\(^{5}\) As OBS is a symptom complex, ‘no treatment’ is an acceptable choice for some patients and caregivers.\(^{23}\)

**First line therapy**

This can be initiated in the primary care setting. It includes a combination of lifestyle interventions (Table 4), bladder training and behavioural modification. Antimuscarinic medications can be added if these measures fail to control symptoms.\(^{1,8,20,23,24}\)

Behavioural treatments (Table 5) have been shown to be effective in older adults, reducing leakage by 50–80%.\(^{26}\) Behavioural training requires a highly motivated patient, and 20–30% will become dry. As behavioural treatments work gradually at first and rely on patient self-management, it is important to follow patients regularly to see sustained behavioural changes.\(^{25}\)

Bladder training (Table 6) has been found to reduce daily urinary frequency and lower daily urinary incontinence compared to antimuscarinics alone.\(^{26}\)

In women with cognitive impairment, prompted and timed voiding toileting programs are recommended.\(^{20}\)

---

**Medical noninvasive pharmacotherapy**

In the primary care setting, patients presenting with typical overactive bladder symptoms can be treated empirically with an antimuscarinic agent and obtain clinical benefit without the need for invasive urodynamic procedures\(^{27}\) (Table 7).

Human bladder contraction is mediated mainly through stimulation of muscarinic receptors in the detrusor muscle by acetylcholine.\(^{12}\) Antimuscarinic agents act during the filling/storage phase of the micturition cycle by inhibiting afferent (sensory) input from the bladder, and directly inhibiting smooth muscle contractility.\(^{24}\) They are competitive antagonists, so with massive release of acetylcholine during micturition the drug effect is decreased and the muscle can contract.\(^{1,9}\)

---

**Table 4. Lifestyle interventions\(^{1,22}\)**

- Altering fluid intake – decreasing to reduce incontinence and frequency, increasing to improve urine concentration
- Smoking cessation
- Dietary modification to eliminate possible bladder irritants (eg. reducing caffeine, alcohol and carbonated beverages). Caffeine is a mild diuretic and bladder irritant, and reducing intake can reduce both urge and stress incontinence
- Weight reduction – central obesity places pressure on the bladder and may worsen urge incontinence\(^{25}\)
- Regulating bowel function to avoid constipation and straining during bowel movements

**Table 5. Behavioural training as first line therapy**

<table>
<thead>
<tr>
<th>Goal</th>
<th>To improve control by teaching the patient to inhibit or interrupt detrusor contractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method</td>
<td>Pelvic floor muscle training with or without biofeedback. Mastering a voluntary contraction of the pelvic floor muscles will help to increase pressure within the urethra, inhibit detrusor contractions and control leakage of urine. Coaching and verbal feedback during vaginal examination can be as effective as biofeedback and electrical stimulation</td>
</tr>
<tr>
<td></td>
<td>• An initial approach is by verbal explanation of the technique reinforced with written materials</td>
</tr>
<tr>
<td></td>
<td>• An effective verbal explanation of proper contraction of the pelvic floor muscles is to tell the patient to tighten up the muscles that they use to hold in flatus. These muscles can also be identified during a pelvic or digital rectal examination</td>
</tr>
<tr>
<td></td>
<td>• An effective exercise prescription for older adults is to contract and relax their pelvic floor muscles for 2 seconds with 15 repetitions, three times per day. Patients should gradually increase the duration of squeeze/relaxations by about 1 second per week, until they achieve 10 second contractions and relaxations. At this point they can begin a maintenance prescription of 10 second contractions and relaxations with 10 repetitions once a day</td>
</tr>
<tr>
<td></td>
<td>• Freeze and squeeze: – when a sense of urgency occurs, instead of rushing to the bathroom, stay still and repeatedly tighten the pelvic floor muscles without relaxing them until the urgency is gone. Walk to the bathroom at a normal pace</td>
</tr>
<tr>
<td></td>
<td>• Repeat as needed</td>
</tr>
</tbody>
</table>

A maintenance program is essential to maintain strength and effectiveness

At least 3 months of supervised pelvic floor muscle training is required to see benefits

Continence management is often best guided by a continence trained professional (eg. nurse or physiotherapist)

**Table 6. Bladder training as first line therapy**

<table>
<thead>
<tr>
<th>Goal</th>
<th>To modify bladder function, reduce voiding frequency, increase bladder capacity and eliminate detrusor overactivity by using scheduled voiding rather than voiding in response to urgency</th>
</tr>
</thead>
</table>
| Method | • The bladder diary is reviewed with the patient, and the longest comfortable interval between voiding is chosen. This interval is the starting point  
|       | • Patients are instructed to empty the bladder on waking and then each time during the day when the interval is reached, and again before going to bed  
|       | • If the patient feels the urge to void during the interval, patients are instructed to use urge suppression techniques, such as distraction or relaxation techniques or self-affirming statements, to get them through to the scheduled voiding time  
|       | • After 1–2 weeks, increase the time interval by 15 minutes, gradually increasing the interval between voids  
|       | • Patients are also encouraged to sit down and take five slow deep breaths, concentrating on the breathing and not the bladder sensation |

A minimum of 6 weeks training is required to see benefits
Antimuscarinic medications

Controlled release compounds are generally better tolerated than immediate release formulations, with similar efficacy. The majority of adverse events associated with antimuscarinic agents are due to inhibition of muscarinic receptors in organs other than the bladder7,28 (Table 8).

If treatment with an antimuscarinic fails due to inadequate symptom control or unacceptable adverse effects, a second antimuscarinic (or duloxetine) can be trialled before considering second or third line therapies23 and a urological opinion. Dry mouth and constipation should be managed before abandoning effective antimuscarinic therapy.23

A Cochrane review29 evaluated anticholinergic medications versus nonpharmacologic treatment of OBS. Symptomatic improvements were more common in patients on anticholinergic drugs compared with bladder training (RR 0.73; 95% CI: 0.59–0.90), and the combination of anticholinergics with bladder training was associated with more improvement than bladder training alone (RR 0.55; 95% CI: 0.32–0.93). There is no clear evidence that one anticholinergic is better than another for treatment of OBS.29

Effects in the elderly

Cognitive dysfunction including memory loss and attention deficits are particular side effects in the elderly.7

### Table 7. Medications available in Australia and proven to be effective for overactive bladder syndrome

<table>
<thead>
<tr>
<th>Drug</th>
<th>Adverse effects</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxybutynin CR 5–15 mg/day</td>
<td>Dry mouth (68%)</td>
<td>Dose response observed</td>
</tr>
<tr>
<td></td>
<td>Constipation (10%)</td>
<td>Take 1 hour before food</td>
</tr>
<tr>
<td>Oxybutynin transdermal</td>
<td>Itchiness at site (14%)</td>
<td>Transderal delivery reduces the typical anticholinergic side effects of dry mouth and constipation</td>
</tr>
<tr>
<td>3.9 mg twice weekly</td>
<td>Erythema at site (8%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dry mouth (7%)</td>
<td></td>
</tr>
<tr>
<td>Tolterodine 2 mg twice</td>
<td>Dry mouth (23%)</td>
<td>Dose dependent effect with immediate release</td>
</tr>
<tr>
<td>per day</td>
<td>Constipation (6%)</td>
<td>Safe in men with bladder outlet obstruction</td>
</tr>
<tr>
<td></td>
<td>Dry eyes (4%)</td>
<td>Expensive, not subsidised on the PBS3,2</td>
</tr>
<tr>
<td>Solifenacin 5–10 mg/day</td>
<td>Dry mouth (26%)</td>
<td>Steady state at 10 days due to long half-life</td>
</tr>
<tr>
<td></td>
<td>Constipation (12%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blurred vision (5%)</td>
<td></td>
</tr>
<tr>
<td>Darifenacin 7.5–15 mg/day</td>
<td>Dry mouth (35%)</td>
<td>Steady state 4–5 hours</td>
</tr>
<tr>
<td></td>
<td>Constipation (21%)</td>
<td>Dose response</td>
</tr>
<tr>
<td>Vaginal oestrogen (topical)</td>
<td>Increased risk of breast cancer</td>
<td>Safety, efficacy and tolerability maintained</td>
</tr>
<tr>
<td>0.5 g cream nightly for</td>
<td>Breast discomfort and pain</td>
<td>with long term use</td>
</tr>
<tr>
<td>2 weeks then twice per</td>
<td>Local reactions</td>
<td>Not subsidised on the PBS</td>
</tr>
<tr>
<td>week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duloxetine 40 mg twice</td>
<td>Nausea (31%)</td>
<td>For postmenopausal women with vaginal atrophy</td>
</tr>
<tr>
<td>per day increasing to</td>
<td>Dry mouth (16%)</td>
<td>Contraindications: past history of breast</td>
</tr>
<tr>
<td>60 mg twice per day</td>
<td>Constipation (14%)</td>
<td>cancer</td>
</tr>
<tr>
<td>day after 4 weeks</td>
<td>Insomnia (13%)</td>
<td></td>
</tr>
<tr>
<td>(for stress urinary</td>
<td>Fatigue (11%)</td>
<td></td>
</tr>
<tr>
<td>incontinence)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 8. Antimuscarinic agents: when to think twice

<table>
<thead>
<tr>
<th>Absolute contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Closed angle glaucoma: anticholinergic medications substantially increase intraocular pressure which may threaten vision if not treated urgently41</td>
</tr>
<tr>
<td>• High doses in ulcerative colitis can lead to paralytic ileus</td>
</tr>
<tr>
<td>• A history of impaired gastric emptying or urinary retention10</td>
</tr>
</tbody>
</table>

**Think twice**

- Elderly patients:  
  - central adverse effects include sedation, confusion, delirium, cognitive impairment and psychotic symptoms45  
- signs of toxicity include urinary retention, agitation, hallucinations, seizures, cardiac arrhythmias and heart block42  
- close monitoring is required20

- Patients who are on other medications metabolised via the hepatic cytochrome P450 (CYP450) family (eg. warfarin, omeprazole, erythromycin, fluoxetine)37

- Men with bladder outlet obstruction:  
  - 45–50% will have concurrent detrusor overactivity13  
  - combination treatment with antimuscarinic agents and an alpha-blocker should be used with caution
may still contribute to cognitive impairment and appropriate monitoring is recommended.

**Prescribing in the elderly**

Oxybutinin can be started at 2.5 mg twice per day. The morning dose can be increased or a lunchtime dose added depending on severity and timing of symptoms. The maximum dose is 5 mg three times per day. High doses are often not well tolerated due to dry mouth, gruity eyes, exacerbation of gastrointestinal reflux and constipation.

**Nonantimuscarinic medications**

Duloxetine (a serotonin noradrenaline reuptake inhibitor) can be effective in both stress and mixed stress and urge incontinence. However, it is currently only Therapeutic Goods Administration (TGA) indicated and Pharmaceutical Benefits Scheme (PBS) subsidised in Australia for major depressive disorder. In clinical practice, most women discontinue duloxetine within 4 weeks due to adverse effects (Table 7).

Failure of conservative and medical treatments warrants urology referral for further investigation with urodynamics, and more invasive therapies may be considered.1,4

**Second line therapy**

Intravesical botulinum toxin A (BoNT/A) prevents acetylcholine release at the neuromuscular junction, resulting in temporary chemodenervation and muscle relaxation for up to 6 months.4 The technique is to place multiple injections under cystoscopic guidance directly into the detrusor.5

Complete continence can be achieved in 40–80% of patients and bladder capacity improved by 56% for up to 6 months.36 Maximal benefit is between 2 and 6 weeks, maintained over 6 months. The injections can be repeated.35

**Third line therapy**

Sacral nerve stimulation involves an implantable electrode in the S3 foramen continuously stimulating the S3 nerve root, in order to stimulate the pudendal nerve. A temporary wire is initially placed under local anaesthetic for 5–7 days in both sides and a voiding diary is kept. An improvement of >50% in any parameters will enable a permanently implanted S3 lead on the side with the best clinical response. There is a potential benefit for up to 5 years in patients with OBS.37

Current indications for sacral nerve stimulation include refractory urge incontinence, refractory urgency and frequency, and idiopathic urinary retention.38

In augmentation cystoplasty, the bladder is enlarged by incorporating a variety of different patches into the native bladder, usually patches of bowel still attached to their mesentery (ileum, caecum or sigmoid colon).39 Indications for bladder augmentation include a small, contracted bladder and a dysfunctional bladder with poor compliance.40

Urinary diversion should be considered only when conservative treatments have failed, and if sacral nerve stimulation and augmentation cystoplasty are not appropriate or unacceptable to the patient.20

**Key points**

- Overactive bladder syndrome is a symptomatic diagnosis consisting of urinary frequency, urgency and nocturia, with or without urge urinary incontinence.
- There is a significant impact on quality of life, which can lead to depression and affect relationships. Patients are often too embarrassed to discuss symptoms with their GP.
- Pathology such as urinary infection, diabetes, bladder stones, malignancy or an underlying neurological cause should be excluded.
- Initial treatment consists of a combination of lifestyle interventions, pelvic floor exercises, bladder training and antimuscarinic medications.
- Care should be taken when prescribing antimuscarinic therapy in the elderly.

**Authors**

Janine Arnold BScMed, MBBS, FRACS, is General Surgical Fellow, Department of Surgery, Bendigo Hospital, Victoria. Janine.arnold@optusnet.com.au Nicholas McLeod BSc, BMed(Hons), FRACS(Urol), is a urological surgeon, Macquarie University Hospital, Sydney, New South Wales

Ruban Thani-Gasalam, Department of Urology, Hôpital Saint Joseph, Paris, France

Prem Rashid MBBS, FRACGP, FRACS(Urol), PhD, is a urological surgeon and Conjoint Associate Professor, Department of Urology, Port Macquarie Base Hospital and University of New South Wales Rural Clinical School, New South Wales.

Conflict of interest: All authors completed the ICJMJE Disclosure of Potential Conflicts of Interest form. Prem Rashid has been a visitor to the American Medical Systems (AMS) US manufacturing facility undertaking a cadaveric dissection clinic and observed operative procedures by high volume implant urologists affiliated with AMS during that time. He also has acted as a consultant for Coloplast, Astra Zeneca, Hospira and Abbott Pharmaceuticals. No commercial organisation initiated or contributed to the writing of the article.

**References**


